Press Releases.

Data to Be Presented Today at the Oppenheimer Rare & Orphan Disease Summit

Regulus Therapeutics Demonstrates Target Engagement in First-Ever Study of RGLS4326 in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Demonstrated Pharmacokinetic Profile Similar to Healthy Volunteers

Completed Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease ("ADPKD")

Definitive Agreement for $19.4 Million in Gross Proceeds

First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease ("ADPKD")

Regulus to Receive Remaining $5 Million Payment for Enrollment Milestone

Proceeds Used to Repay Debt Principal with Oxford Finance

Completion of Dosing in Phase 1 Multiple Ascending Dose Study ("MAD") of RGLS4326 in Healthy Volunteers for Autosomal Dominant Polycystic Kidney Disease ("ADPKD")